Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 8/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | KDM5A | P29375 | 3/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24860007 | 0.99 | NAAA (0.51) | NAAAHPGDKDM5APHF8KDM2A | |
| SCHEMBL22181049 | 0.99 | NAAA (0.51) | NAAAHPGDKDM5APHF8KDM2A | |
| SCHEMBL20801422 | 0.99 | NAAA (0.51) | NAAAHPGDKDM5APHF8KDM2A | |
| SCHEMBL18779827 | 0.99 | NAAA (0.51) | NAAAHPGDKDM5APHF8KDM2A | |
| SCHEMBL24622843 | 0.98 | NAAA (0.47) | NAAAHPGDKDM5APHF8KDM2A | |
| SCHEMBL24593481 | 0.89 | L3MBTL1 (0.41) | NAAAHPGDPSMB8 | |
| SCHEMBL9752033 | 0.89 | L3MBTL1 (0.41) | NAAAHPGDPSMB8 | |
| SCHEMBL24860099 | 0.86 | NAAA (0.40) | NAAAEPHX1ASAH1PSMB8 | |
| SCHEMBL20801484 | 0.86 | NAAA (0.40) | NAAAEPHX1ASAH1PSMB8 | |
| SCHEMBL21895267 | 0.86 | NAAA (0.36) | NAAAHPGDPSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | SHIONOGI & CO., LTD. (JP) | 2023-05-02 | — | — | US | disclosed |
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | SHIONOGI & CO., LTD. (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20200384010-A1 | COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID | SHIONOGI & CO., LTD. (JP) | 2020-12-10 | — | — | US | disclosed |
| EP-3603648-A1 | COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID | Shionogi & Co., Ltd (JP) | 2020-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | FABP1, POLRMT, SREBF1 | NAAA 963/4885HPGD 4766/4885KDM5A 4221/4885 |
| US-20200384010-A1 | COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID | FABP1, POLRMT, SREBF1 | NAAA 963/4885HPGD 4766/4885KDM5A 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.